Patents by Inventor Keith Bowman
Keith Bowman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10792361Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: August 29, 2018Date of Patent: October 6, 2020Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
-
Patent number: 10729775Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: June 28, 2018Date of Patent: August 4, 2020Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Publication number: 20180369386Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: August 29, 2018Publication date: December 27, 2018Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
-
Patent number: 10124065Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: March 6, 2014Date of Patent: November 13, 2018Assignee: Novartis AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
-
Publication number: 20180296677Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: June 28, 2018Publication date: October 18, 2018Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Publication number: 20180137929Abstract: A device includes a first set of storage elements, a second set of storage elements, and a bias circuit configured to generate a test bias signal to bias the first set of storage elements and the second set of storage elements. The device further includes a sensor circuit configured to receive a first signal from at least a first storage element of the first set of storage elements in response to the test bias signal and to receive a second signal from at least a second storage element of the second set of storage elements in response to the test bias signal. The sensor circuit is further configured to generate a third signal having a delay characteristic indicating a wear difference between the first storage element and the second storage element.Type: ApplicationFiled: November 14, 2016Publication date: May 17, 2018Inventors: Giby Samson, Erik Hedberg, Francois Atallah, Keith Bowman
-
Publication number: 20170196979Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: September 27, 2016Publication date: July 13, 2017Applicant: Novartis AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Patent number: 9504747Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: March 7, 2014Date of Patent: November 29, 2016Assignee: Novartis AGInventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura Ellen West, Thomas Zabawa, Junping Zhao
-
Publication number: 20160106842Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: March 6, 2014Publication date: April 21, 2016Inventors: Jeremy Lee BARYZA, Rohan Eric John BECKWITH, Keith BOWMAN, Crystal BYERS, Tanzina FAZAL, Gabriel Grant GAMBER, Cameron Chuck-Munn LEE, Ritesh Bhanudasji TICHKULE, Chandra VARGEESE, Shuangxi WANG, Laura WEST, Thomas ZABAWA, Junping ZHAO
-
Patent number: 9301923Abstract: Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.Type: GrantFiled: March 4, 2014Date of Patent: April 5, 2016Assignee: NOVARTIS AGInventors: Jeremy Baryza, Keith Bowman, Andrew Geall, Tanzina Labonte, Cameron Lee, Chandra Vargeese, Laura West, Junping Zhao
-
Publication number: 20140309277Abstract: Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.Type: ApplicationFiled: March 4, 2014Publication date: October 16, 2014Applicant: NOVARTIS AGInventors: Jeremy BARYZA, Keith BOWMAN, Andrew GEALL, Tanzina LABONTE, Cameron LEE, Chandra VARGEESE, Laura WEST, Junping ZHAO
-
Publication number: 20140303232Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: ApplicationFiled: March 7, 2014Publication date: October 9, 2014Applicant: NOVARTIS AGInventors: Jeremy Lee BARYZA, Rohan Eric John BECKWITH, Keith BOWMAN, Crystal BYERS, Tanzina FAZAL, Gabriel Grant GAMBER, Cameron Chuck-munn LEE, Ritesh Bhanudasji TICHKULE, Chandra VARGEESE, Shuangxi WANG, Laura Ellen West, Thomas ZABAWA, Junping ZHAO
-
Patent number: 8301970Abstract: Sequential circuits with error-detection are provided. They may, for example, be used to replace traditional master-slave flip-flops, e.g., in critical path circuits to detect and initiate correction of late transitions at the input of the sequential. In some embodiments, such sequentials may comprise a transition detector with a time borrowing latch.Type: GrantFiled: September 26, 2008Date of Patent: October 30, 2012Assignee: Intel CorporationInventors: Keith Bowman, James Tachanz, Nam Sung Kim, Janice Lee, Chris Wilkerson, Shih-Lien L. Lu, Tanay Karnlk, Vivek De
-
Publication number: 20110200582Abstract: Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.Type: ApplicationFiled: December 21, 2010Publication date: August 18, 2011Applicant: NOVARTIS AGInventors: Jeremy BARYZA, Keith BOWMAN, Andrew GEALL, Tanzina LABONTE, Cameron LEE, Chandra VARGEESE, Laura WEST, Junping ZHAO
-
Patent number: 7893249Abstract: Method for synthesis, deprotection, and/or purification of nucleic acid molecules, such as oligonucleotides comprising one or more ribonucleotides. Such nucleic acid molecules include siRNA, dsRNA, ribozymes, antisense, and aptamers.Type: GrantFiled: December 7, 2009Date of Patent: February 22, 2011Assignee: Sirna Therapeutics, Inc.Inventors: Keith Bowman, Christopher Shaffer, Chandra Vargeese
-
Publication number: 20100197901Abstract: Method for synthesis, deprotection, and/or purification of nucleic acid molecules, such as oligonucleotides comprising one or more ribonucleotides. Such nucleic acid molecules include siRNA, dsRNA, ribozymes, antisense, and aptamers.Type: ApplicationFiled: December 7, 2009Publication date: August 5, 2010Applicant: SIRNA THERAPEUTICS, INC.Inventors: KEITH BOWMAN, CHRISTOPHER SHAFFER, CHANDRA VARGEESE
-
Publication number: 20100079184Abstract: Sequential circuits with error-detection are provided. They may, for example, be used to replace traditional master-slave flip-flops, e.g., in critical path circuits to detect and initiate correction of late transitions at the input of the sequential. In some embodiments, such sequentials may comprise a transition detector with a time borrowing latch.Type: ApplicationFiled: September 26, 2008Publication date: April 1, 2010Inventors: Keith Bowman, James Tachanz, Nam Sung Kim, Janice Lee, Chris Wilkerson, Shlh-Lian L. Lu, Tanay Kamlk, Vivek De
-
Patent number: 7655790Abstract: Method for synthesis, deprotection, and/or purification of nucleic acid molecules, such as oligonucleotides comprising one or more ribonucleotides. Such nucleic acid molecules include siRNA, dsRNA, ribozymes, antisense, and aptamers.Type: GrantFiled: January 12, 2005Date of Patent: February 2, 2010Assignee: Sirna Therapeutics, Inc.Inventors: Chandra Vargeese, Christopher Shaffer, Keith Bowman
-
Publication number: 20050215777Abstract: Method for synthesis, deprotection, and/or purification of nucleic acid molecules, such as oligonucleotides comprising one or more ribonucleotides. Such nucleic acid molecules include siRNA, dsRNA, ribozymes, antisense, and aptamers.Type: ApplicationFiled: January 12, 2005Publication date: September 29, 2005Applicant: Sirna Therapeutics, Inc.Inventors: Chandra Vargeese, Christopher Shaffer, Keith Bowman